The ASCEND Study – Aspirin for Prevention of Cardiovascular Events
Jul 6, 2019
Editor: David L. Joffe, BSPharm, CDE, FACA
Author: Marian Ayad, BPharm, PharmD candidate, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences
The study findings demonstrate a balance between cardiovascular protection and major bleeding.
Aspirin is known to reduce the risk of cardiovascular events and increase the risk of bleeding. It is beneficial for patients with cardiovascular disease, but what is not clear is the balance of benefits and hazards for the prevention of primary cardiovascular events in patients with diabetes who have not had a cardiovascular event. Previous studies conducted failed to report clear data on whether the benefits for using aspirin among people with diabetes outweigh the risks. Past retrospective meta-analyses have suggested that low-dose aspirin can reduce the incidence of gastrointestinal cancers, with the effects appearing after long exposure and long follow up to 20 years.
The ASCEND study, (A Study of Cardiovascular Events in Diabetes), was conducted to assess the efficacy and safety of aspirin EC 100mg daily, compared with placebo, in people with diabetes without cardiovascular disease at the start of the trial....
Agreement to pay later is required for access to the full text of this article. You will be charged only after your use reaches $5.00 (US) of site content. The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control.